Literature DB >> 18006809

Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice.

Hiroyuki Kawagoe1, Ayten Kandilci, Tanya A Kranenburg, Gerard C Grosveld.   

Abstract

N-MYC encodes a basic helix-loop-helix/leucine zipper (bHLH/LZ) transcription factor that is frequently overexpressed in human neuroblastoma. N-MYC overexpression has also been reported in human acute myeloid leukemias (AML), which we show here is a frequent event. Myeloid cells in N-Myc-overexpressing mouse bone marrow hyperproliferate but those in c-MYC-overexpressing bone marrow do not. The NH(2)-terminal transactivation domain, nuclear localization signal, and bHLH/LZ domain of N-Myc are essential for this effect. Microarray analysis revealed 969 differentially expressed genes between N-Myc- and c-MYC-overexpressing myeloid cells. N-Myc-overexpressing cells showed decreased transforming growth factor beta signaling and increased c-Jun-NH(2)-kinase signaling, both of which are associated with proliferation and leukemic transformation of myeloid cells. Mice transplanted with bone marrow expressing wild-type N-Myc developed clonal and transplantable AML after approximately 1 month; those transplanted with bone marrow expressing mutant N-Myc did not. Twist, a known suppressor of the p19Arf/p53 pathway, was up-regulated in all tumors. These results show that N-Myc overexpression is highly oncogenic in mouse myeloid cells and suggest that N-MYC up-regulation contributes to human myeloid leukemogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18006809     DOI: 10.1158/0008-5472.CAN-07-1118

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

Review 1.  The super elongation complex (SEC) family in transcriptional control.

Authors:  Zhuojuan Luo; Chengqi Lin; Ali Shilatifard
Journal:  Nat Rev Mol Cell Biol       Date:  2012-08-16       Impact factor: 94.444

Review 2.  Transcription factor-mediated reprogramming toward hematopoietic stem cells.

Authors:  Wataru Ebina; Derrick J Rossi
Journal:  EMBO J       Date:  2015-02-20       Impact factor: 11.598

3.  Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

Authors:  Zhifu Xiang; Hui Luo; Jacqueline E Payton; Jennifer Cain; Timothy J Ley; Joseph T Opferman; Michael H Tomasson
Journal:  J Clin Invest       Date:  2010-05-17       Impact factor: 14.808

4.  Chemotherapy-induced hypomethylation of N-myc downstream-regulated gene 4 in the bone marrow of patients with acute myeloid leukemia.

Authors:  Qingxiao Hong; Xiaoying Chen; Huadan Ye; Xiaodong Wu; Xuejing Wang; Lingyan Kong; Yongming Xia; Shiwei Duan
Journal:  Oncol Lett       Date:  2017-03-10       Impact factor: 2.967

5.  The helix-loop-helix transcription factor TWIST is dysregulated in myelodysplastic syndromes.

Authors:  Xiang Li; A Mario Marcondes; Theodore A Gooley; H Joachim Deeg
Journal:  Blood       Date:  2010-06-18       Impact factor: 22.113

6.  Induction of neuronal and tumor-related genes by adenovirus type 12 E1A.

Authors:  Hancheng Guan; Jim F Williams; Robert P Ricciardi
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

7.  Effects of the NUP98-DDX10 oncogene on primary human CD34+ cells: role of a conserved helicase motif.

Authors:  E R Yassin; A M Abdul-Nabi; A Takeda; N R Yaseen
Journal:  Leukemia       Date:  2010-03-25       Impact factor: 11.528

8.  Regulation of p21 by TWIST2 contributes to its tumor-suppressor function in human acute myeloid leukemia.

Authors:  X Zhang; W Ma; J Cui; H Yao; H Zhou; Y Ge; L Xiao; X Hu; B-H Liu; J Yang; Y-Y Li; S Chen; C J Eaves; D Wu; Y Zhao
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

Review 9.  MYC oncogene in myeloid neoplasias.

Authors:  M Dolores Delgado; Marta Albajar; M Teresa Gomez-Casares; Ana Batlle; Javier León
Journal:  Clin Transl Oncol       Date:  2012-08-22       Impact factor: 3.405

Review 10.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.